Last reviewed · How we verify

Dinoprostone 10mg

Centre Hospitalier Universitaire de Besancon · FDA-approved active Small molecule Quality 5/100

Dinoprostone 10mg is a Small molecule drug developed by Centre Hospitalier Universitaire de Besancon. It is currently FDA-approved. Also known as: Dinoprostone induction.

At a glance

Generic nameDinoprostone 10mg
Also known asDinoprostone induction
SponsorCentre Hospitalier Universitaire de Besancon
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Dinoprostone 10mg

What is Dinoprostone 10mg?

Dinoprostone 10mg is a Small molecule drug developed by Centre Hospitalier Universitaire de Besancon.

Who makes Dinoprostone 10mg?

Dinoprostone 10mg is developed and marketed by Centre Hospitalier Universitaire de Besancon (see full Centre Hospitalier Universitaire de Besancon pipeline at /company/centre-hospitalier-universitaire-de-besancon).

Is Dinoprostone 10mg also known as anything else?

Dinoprostone 10mg is also known as Dinoprostone induction.

What development phase is Dinoprostone 10mg in?

Dinoprostone 10mg is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing